Can targeted radiation tame advanced prostate cancer? a registry aims to find out

NCT ID NCT05995236

Terminated Disease control Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study collects real-world data from people with PSMA-positive metastatic castration-resistant prostate cancer who receive PSMA radionuclide therapy. The goal is to track patient characteristics, treatment responses, and survival outcomes. By gathering this information, researchers hope to better understand how this targeted therapy performs in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA radionuclide therapy
What this could lead to: If successful, this could help clarify how well PSMA radionuclide therapy works in real-world patients, potentially guiding better treatment decisions for advanced prostate cancer.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove the therapy's effectiveness. Results may vary due to differences in patient care and follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.